FDA Expands Omisirge (omidubicel-onlv) Approval for Severe Aplastic Anemia in Children 6 Years and Older

  • Post category:News
  • Reading time:2 mins read

The U.S. Food and Drug Administration (FDA) has expanded approval for Omisirge (omidubicel-onlv) to treat severe aplastic anemia in children aged 6 years and older. Omisirge was previously approved for…

Continue ReadingFDA Expands Omisirge (omidubicel-onlv) Approval for Severe Aplastic Anemia in Children 6 Years and Older